Last updated: April 25, 2026
Who Supplies IBRANCE (palbociclib) and Its Key Inputs?
IBRANCE is palbociclib, a branded small-molecule oncology drug marketed by Pfizer. The active ingredient is synthesized and supplied through Pfizer’s global manufacturing and contract manufacturing network, while finished dosage supply and packaging are handled through Pfizer and select third-party manufacturers operating under Pfizer’s quality system and regulatory filings.
Who manufactures the active ingredient (API) for IBRANCE?
IBRANCE’s API (palbociclib) is produced by Pfizer-controlled manufacturing sites and, where applicable, by qualified third-party API manufacturers named in regulatory submissions and drug master files/established manufacturing disclosures tied to marketed product. Public dossier-level traceability typically ties palbociclib API manufacturing to Pfizer or Pfizer-authorized sites listed across U.S. FDA and international registration packages.
Who manufactures the finished dosage form of IBRANCE?
Finished IBRANCE capsules are manufactured by Pfizer’s internal manufacturing network and/or contracted finished dosage manufacturers listed in product registration documentation. Packaging operations (including blistering/bottling and labeling) can be performed by Pfizer packaging sites or qualified contract packaging providers.
What contract manufacturing footprint applies to IBRANCE?
For high-volume branded oncology products like IBRANCE, supply chain execution typically splits across:
- API synthesis sites (internal or contract)
- Drug product manufacturing sites (internal or contract)
- Primary packaging and labeling sites (internal or qualified contract)
The exact supplier list depends on:
- Country-specific marketing authorization
- Strength and dosage form
- Lot release geography
- Changes in manufacturing sites over time
Because supplier identification requires mapping to specific regulatory product listings, approvals, and site-change histories, a complete, validated “supplier roster” cannot be produced from the limited information provided.
What can be stated from the brand ownership and product structure?
- Marketing Authorization Holder (global): Pfizer
- Drug substance: palbociclib
- Drug product: IBRANCE capsules (multiple strengths)
This establishes the governance chain for supplier qualification and product release, but it does not uniquely identify each external supplier and site without dossier-level manufacturer site disclosure by jurisdiction and time.
Key supplier categories to diligence for IBRANCE supply risk
Even when the exact site list cannot be enumerated from the provided input, the due-diligence targets for IBRANCE supply contracts are consistent across pharmaceutical small molecules:
-
API synthesis supplier
- Controls: polymorph/form, particle size distribution, residual solvents, impurities profile
- Typical risk drivers: precursor availability, yield losses, reactor capacity, solvent restrictions
-
Drug product (capsule) manufacturer
- Controls: blend uniformity, capsule fill weight, dissolution profile, stability program
- Typical risk drivers: granulation/batch failure, humidity control, encapsulation throughput
-
Packaging and labeling supplier
- Controls: blister/bottle integrity, printed NDC/lot tracking, serialization if required
- Typical risk drivers: label component lead times, line downtime, rework from misprints
-
Quality and release operations
- Controls: QMS compliance, batch disposition, deviation management
- Typical risk drivers: regulatory observations, audit findings, documentation backlogs
Key Takeaways
- IBRANCE is palbociclib and is marketed by Pfizer, which governs supplier qualification and batch release.
- IBRANCE supply chains typically use a split model across API, finished drug product, and packaging/labeling under Pfizer’s quality system.
- A complete, accurate supplier roster requires mapping to site-specific regulatory disclosures by jurisdiction, strength, and release history; this cannot be derived from the information provided.
FAQs
1) Is IBRANCE manufactured by Pfizer only?
IBRANCE manufacturing is typically executed through Pfizer sites and can include qualified contract manufacturers for drug product and/or packaging under Pfizer quality oversight.
2) Who supplies the palbociclib API used in IBRANCE?
The palbociclib API is supplied by Pfizer-controlled manufacturing and/or Pfizer-authorized qualified suppliers, with specific site identity varying by regulatory jurisdiction and time.
3) Are packaging and labeling done by the same supplier as capsule manufacturing?
Packaging/labeling can be performed by Pfizer packaging sites or qualified contract packaging providers, separate from drug product manufacturing.
4) Do suppliers differ by IBRANCE strength (e.g., 75 mg vs 100 mg vs other strengths)?
Yes. Different strengths can involve different manufacturing campaigns, line assignments, and release geographies.
5) Where do you find the definitive supplier list for IBRANCE?
In jurisdiction-specific regulatory product submissions and site disclosures that enumerate manufacturing and packaging/labeling operations tied to marketed lots.
References (APA)
[1] Pfizer. (n.d.). IBRANCE (palbociclib) prescribing information and product documentation. Pfizer.
